The 2025 NCCN Guideline Update for CA LEMS in Small Cell Lung Cancer: What Changed and What Still Needs to Change, Plus Cancer-Directed Treatment as Primary Intervention

Dr. Sen addresses the significance of the 2025 NCCN SCLC guideline update explicitly naming CA LEMS symptom recognition (proximal weakness paired with autonomic dysfunction) and recommending P/Q-type and N-type VGCC antibody testing under the neurologic workup section, with early subspecialty consultation recommended. Because NCCN is the primary reference document oncologists consult when evaluating patients, this inclusion carries real weight; it transforms CA LEMS recognition from clinician-dependent awareness to default guideline-directed practice.

However, the guideline alone will not close the underdiagnosis gap. What it does not yet provide is specific testing triggers, structured screening algorithms, or integrated workflows defining how oncology, neurology, and laboratory medicine coordinate once testing is initiated. Individual institutions must build their own pathways using the guideline as the foundation.

Dr. Primdahl adds that the guideline update is clinically meaningful precisely because testing for and treating CA LEMS has direct practical consequences: optimizing CA LEMS symptom control improves functional status and performance status, which enables patients to tolerate more aggressive cancer-directed therapy, creating a clinically virtuous cycle.

Treating the underlying SCLC is the primary intervention for paraneoplastic CA LEMS, as tumor control reduces antigen drive by decreasing VGCC-expressing tumor burden and thereby reducing autoantibody production. However, many patients retain LEMS symptoms despite cancer response, making CA LEMS-specific treatment necessary in most cases. An important unresolved question is whether cancer-directed therapies including immune checkpoint inhibitors might accelerate the autoimmune process in CA LEMS. This question has no prospective data yet, requiring individualized close multidisciplinary monitoring.